Page 20 - Flipbook
P. 20
ARCHES: Time to Castration Resistance
100
Free of castration resistance (%)
90
Enzalutamide + ADT
80
70
60
50
40
Placebo + ADT
30
ENZA + ADT PBO + ADT
20
Median, month (95% CI) NR (NR, NR) 13.8 (11.3 to 16.8)
10 HR (95% CI) 0.28 (0.22 to 0.36)
p value <.001
0
0 3 6 9 12 15 18 21 24 27 30 33
Months
Patients at Risk
ENZA + ADT 574 514 492 389 262 150 69 26 6 1 1 0
PBO + ADT 576 475 392 279 162 91 31 10 0 0 0 0
The median time to progression to mCRPC was 13.8 month for patients on ADT alone
Armstrong et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic
Hormone-Sensitive Prostate Cancer (Data Supplement); Published online at JCO.org on July 30 2019.
